Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis

Elevated ribosome biogenesis in oncogene‐driven cancers is commonly targeted by DNA‐damaging cytotoxic drugs. Our previous first‐in‐human trial of CX‐5461, a novel, less genotoxic agent that specifically inhibits ribosome biogenesis via suppression of RNA polymerase I (Pol I) transcription, revealed...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:EMBO J
Egile Nagusiak: Kusnadi, Eric P, Trigos, Anna S, Cullinane, Carleen, Goode, David L, Larsson, Ola, Devlin, Jennifer R, Chan, Keefe T, De Souza, David P, McConville, Malcolm J, McArthur, Grant A, Thomas, George, Sanij, Elaine, Poortinga, Gretchen, Hannan, Ross D, Hannan, Katherine M, Kang, Jian, Pearson, Richard B
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2020
Gaiak:
Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7604608/
https://ncbi.nlm.nih.gov/pubmed/32945574
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/embj.2020105111
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak